Crossmark

The impact of tocilizumab treatment on the severity of inflammation and survival rates in sepsis is significantly influence by the timing of administration

Crossref DOI link: https://doi.org/10.1007/s10787-025-01649-6

Published Online: 2025-02-15

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tavaci, Taha https://orcid.org/0000-0002-8284-8317
Halici, Zekai

Cadirci, Elif

Ozkaraca, Mustafa

Kasali, Kamber
Funding

Funding for this research was provided by:

Atatürk Üniversitesi (TDK-2021-9459)

Sakarya University
License Information

Text and Data Mining valid from 2025-02-15

Version of Record valid from 2025-02-15
More Information

Article History

Received: 10 September 2024

Accepted: 6 January 2025

First Online: 15 February 2025

Change Date: 26 April 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10787-025-01748-4

Updates are available Correction dated 2025-04-26

Click to view Correction: https://doi.org/10.1007/s10787-025-01748-4